News for Stereotaxis, Inc. (STXS)

Stereotaxis (STXS) is gearing up to present a live demonstration of its groundbreaking GenesisX Robotic System during the upcoming Heart Rhythm Symposium (HRS)

Fourth Quarter Revenue: $6.3 million, a 39% increase year-over-year.System Revenue (Q4 2024): $1.4 million, up from $0.1 million in Q4 2023.Recurring Revenue (

Mar 03, 2025 / 01:30PM GMTOperator Good morning. Thank you for joining us for Stereotaxis fourth-quarter and full-year 2024 earnings conference call. Certain st

Stereotaxis, Inc. (NYSE:STXS) Q4 2024 - Earnings Conference Call March 3, 2025 8:30 AM ETCompany ParticipantsDavid Fischel - Chairman and CEOKimberly Peery...

Stereotaxis (STXS) delivered earnings and revenue surprises of -80% and 9.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $6.3 million for Q4 2024, slightly below the estimated $6.43 million, but marking a 39% increase year-over-year.Earnings Per Share (EPS): Reported at

**media[555336]**

Stereotaxis Inc (STXS) is set to release its Q4 2024 earnings on Mar 3, 2025. The consensus estimate for Q4 2024 revenue is $6.43 million, and the earnings are

The robotics industry, which has grown modestly over the past few years, has suddenly picked up pace after the emergence of AI.

Stereotaxis, Inc. (STXS) experienced a notable stock increase of 6.16%, reaching $2.33 per share with a trading volume of 280,309 shares. Despite a net loss of

Harvard Bioscience (HBIO) shares dropped 5.13%, trading at $2.13 with a volume of 73,085 shares. The turnover rate stood at 0.17%, and the stock experienced a 7

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

MHUA (MHUA) experienced a notable stock price increase of 5.53%, reaching $0.557 per share, with a trading volume of 96,731 shares and a turnover rate of 0.37%.

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Harvard Bioscience (HBIO) experienced a significant drop, falling 5.31%. The stock is now priced at $2.32 per share with a trading volume of 89,737 shares and a

Nov 11, 2024 / 09:30PM GMTOperator Good afternoon. Thank you for joining us for Stereotaxis third quarter 2024 earnings conference call. Certain statements duri

Stereotaxis, Inc. (NYSE:STXS) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ETCompany ParticipantsDavid Fischel - Chairman and Chief Executive...

Stereotaxis (STXS) delivered earnings and revenue surprises of -60% and 35.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and...